# Rapamycin and Longevity in Germany

Rapamycin (sirolimus) is a prescription immunosuppressant, not a supplement, and it is the most reliable life-extender in animal studies (median lifespan +9% to +13% in mice), but no human trial has yet shown it extends life or healthspan. The largest longevity study so far, PEARL (2025), missed its main goal of reducing visceral fat. In Germany it is approved only for transplant and LAM, so any longevity use is off-label, self-paid (roughly €240-310/month at the official price), and needs a doctor willing to monitor you with regular labs.

The mTOR story in plain words, what the studies really show, and how off-label use works legally here.

## On this page

- What is Rapamycin?
- Why Does mTOR Matter for Aging?
- What Do Human Trials Actually Show?
- Is Rapamycin Legal for Longevity in Germany?
- How Do You Talk to a Doctor About Rapamycin?

## FAQ

- Does rapamycin make people live longer?
- Can my GP prescribe rapamycin for longevity?
- Can I just order rapamycin online from abroad?
- What dose do longevity protocols use?
- What are the main risks?

## Sources

- Harrison DE, Strong R, Sharp ZD, et al.. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. https://doi.org/10.1038/nature08221
- Mannick JB, Del Giudice G, Lattanzi M, et al.. (2014). mTOR inhibition improves immune function in the elderly (RAD001/everolimus). Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3009892
- Mannick JB, Morris M, Hockey HP, et al.. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly (RTB101 ± everolimus). Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaq1564
- Mannick JB, Teo G, Bernardo P, Quinn D, Russell K, Klickstein L, Marshall W, Shergill S. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. Lancet Healthy Longevity. https://doi.org/10.1016/S2666-7568(21)00062-3
- Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, Zalzala S. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). https://doi.org/10.18632/aging.206235
- European Medicines Agency. (2001). Rapamune (sirolimus) European Public Assessment Report. https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune
- Bundesministerium der Justiz. (2024). §73 Arzneimittelgesetz — Verbringungsverbot. https://www.gesetze-im-internet.de/amg_1976/__73.html
- Euvrard S, Morelon E, Rostaing L, et al.. (2012). Sirolimus and secondary skin-cancer prevention in kidney transplantation (TUMORAPA). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1204166

_Full guide: https://longevity-austria.com/en/guide/rapamycin-deutschland_

---

_Canonical: https://longevity-austria.com/en/guide/rapamycin-deutschland · Part of Longevity Cities · Updated 2026-05-22_